NCT00857285

Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker "Olmesartan Medoxomil" Versus "Losartan" in Patients With Mild to Moderate Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 130 (actual)
• Sponsor: Daiichi Sankyo · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	olmesartan medoxomil	olmesartan medoxomil oral tablets, once daily for up to 12 weeks
DRUG	losartan potassium	losartan oral tablets, once daily for up to 12 weeks

Timeline

• Start date: 2002-05-01
• Primary completion: 2003-08-01
• Completion: 2003-09-01
• First posted: 2009-03-06
• Last updated: 2009-07-23
• Results posted: 2009-07-23

Locations

3 sites across 1 country: Taiwan